Nuvectis Pharma, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Nuvectis Pharma, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($26.44M) | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | ($19.00M) | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | ($22.26M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | ($19.09M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($12.89M) | Mar 8, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($27.57M) | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | ($19.85M) | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | ($22.90M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | ($19.23M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($12.89M) | Mar 8, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.15M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $12.92M | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $15.38M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $13.23M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $9.55M | Mar 8, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($16.01M) | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | ($12.25M) | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | ($15.95M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | ($13.56M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($9.50M) | Mar 8, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.71M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $18.61M | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $19.19M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $20.41M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $6.66M | Mar 8, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.30M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $8.89M | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $6.98M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $6.19M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $2.42M | Mar 8, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.41M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $9.71M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $12.20M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $14.22M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | ($11.01M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | ($10.0K) | Mar 8, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($99.69M) | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | ($73.25M) | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | ($54.25M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | ($31.99M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($12.90M) | Mar 8, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.63M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $18.53M | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $19.13M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $19.99M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $5.74M | Mar 8, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | (3) | Mar 8, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | (3) | Mar 8, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 25.68M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | 19.50M | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | 17.42M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | 15.19M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | 4.51M | Mar 8, 2023 |